ICUI - ICU Medical, Inc.

ICU Medical manufactures and sells infusion therapy devices and consumables, including the Clave needlefree IV connector system, infusion pumps, and oncology drug delivery sets used in hospital and clinical settings. The business model is institutional B2B, selling to hospitals, health systems, and ambulatory care centers through direct sales and group purchasing organization contracts, with recurring revenue from high-volume disposable consumables. Annual revenue is approximately $2.2B, with the majority generated in North America, though the 2022 acquisition of Smiths Medical meaningfully expanded its international presence across Europe and Asia-Pacific. Core end markets are critical care, oncology infusion, and hospital pharmacy automation.

Past Year Trends

• Adjusted EBITDA grew 22% year-over-year in Q4 2024 to $105.5M, and Q1 2025 adjusted EPS rose 79% to $1.72 versus $0.96 in Q1 2024, driven by ongoing Smiths Medical integration synergies and operational leverage. (Bullish)
• ICU Medical closed its Oakdale, Minnesota manufacturing facility in late 2024 with approximately 83 job cuts, incurring $17.1M in restructuring and integration charges in Q2 2024 alone, as the company continued to consolidate operations following the 2022 Smiths Medical acquisition. (Neutral)
• ICU Medical received FDA 510(k) clearance for the Plum Solo, Plum Duo precision IV pumps, and LifeShield Infusion Safety Software Suite in 2025, completing the initial commercial launch of its IV Performance Platform, which positions the company to compete for new hospital formulary placements. (Bullish)

Next Year Trends

• ICU Medical's 2025 adjusted EBITDA guidance of $395–$425M (up from approximately $355–$365M in 2024) depends on continued Smiths Medical synergy capture, and any integration execution shortfall or incremental restructuring charges could pressure the $6.55–$7.25 adjusted EPS target. (Bullish)
• Foreign currency headwinds are expected to reduce reported revenue growth by 100–150 basis points in 2025, representing a meaningful drag given the company's international revenue exposure inherited from the Smiths Medical acquisition. (Bearish)
• The completed IV Performance Platform — Plum Solo, Plum Duo, and LifeShield software — will face its first full commercialization cycle in 2025–2026, with hospital contract wins or losses on large GPO agreements serving as the primary volume catalyst or risk for infusion pump revenue growth. (Bullish)

Red Flags

[Securities Fraud / Investigation] Securities fraud investigation announced by Block & Leviton (April 24, 2025) and The Law Offices of Frank R. Cruz (April 22, 2025) into ICU Medical, Inc. (ICUI) for potential securities law violations following an FDA warning letter alleging the company made multiple unapproved changes to infusion pump devices (Medfusion Model 4000 and CADD Solis VIP) that could affect device safety or effectiveness. — Business Wire / GlobeNewswire, April 22–24, 2025